Micke et al [17] showed that patients with c-Kit negative extensive stage SCLC have higher median survival rates and negligible response to old-generation chemotherapy (eg, cyclophosphamide and adriamycin combination, or single-agent cyclophosphamide, adriamycin, or etoposide). This evidence concerns the gene KIT and small cell lung carcinoma.